In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chelsea Therapeutics International, Ltd.

http://www.chelseatherapeutics.com

Latest From Chelsea Therapeutics International, Ltd.

Finance Watch: More Job Cuts As Companies Prioritize Cash Conservation

Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US. 

Financing Strategy

Quanta CEO Speaks On US Expansion, Talent Acquisition, And Addressable Markets

Since closing its $245m funding raise, Quanta Dialysis Technologies has been scaling up its commercial infrastructure and bolstering its US presence.

Innovation Renal

SMA Market Snapshot: Future Spinraza Patent Loss Makes Room For Promising Myostatin Inhibitors

While spinal muscular atrophy therapies Evrysdi and Zolgensma have gained ground at the expense of pioneer Spinraza, emerging myostatin inhibitors promise a complementary mechanism that could enhance functional outcomes.

Market Snapshot Neurology

Japan Lifts Decades-Old Bans On Somatropin In Diabetes, IFNβ In Pregnancy

Japan cautiously lifts decades-old bans on somatropin’s use in diabetic patients and interferon beta 1a/1b in pregnant patients, judging benefits can outweigh risks and following requests from doctors and pharma firms to consider patients.

Japan Regulation
See All

Company Information

UsernamePublicRestriction

Register